Patents by Inventor Jai Pal Singh

Jai Pal Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for preparation of letrozole and its intermediates
    Patent number: 8198460
    Abstract: The present invention relates to an improved process for preparation of the non-steroidal aromatase inhibitor drug, Letrozole of formula (I) and its intermediates, 4-[1-(1,2,4-triazolyl)methyl]-benzonitrile of formula (IV) and 4-[1-(1,2,4-triazolyl)methyl]-benzonitrile hydrochloride of formula (VII), all having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and industrially viable.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: June 12, 2012
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Vimal Kumar Shrawat, Jai Pal Singh, Rajesh Prasad Nautiyal
  • PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES
    Publication number: 20100234617
    Abstract: The present invention relates to an improved process for preparation of the non-steroidal aromatase inhibitor drug, Letrozole of formula (I) and its intermediates, 4-[1-(1,2,4-triazolyl)methyl]-benzonitrile of formula (IV) and 4-[1-(1,2,4-triazolyl)methyl]-benzonitrile hydrochloride of formula (VII), all having a purity of ?99%, which is simple, convenient, economical, does not use hazardous chemicals and industrially viable.
    Type: Application
    Filed: January 16, 2008
    Publication date: September 16, 2010
    Applicant: FRESENIUS KABI ONCOLOGY LTD.
    Inventors: Vimal Kumar Shrawat, Jai Pal Singh, Rajesh Prasad Nautiyal
  • Modified platelet factor-4
    Patent number: 5935928
    Abstract: The present invention is based of the discovery of two modified forms of human platelet factor-4, herein named MPF-4 and CPF-4, which were isolated from serum free culture medium of lipopolysaccharide-stimulated peripheral blood leukocytes. Amino acid sequence determination revealed that MPF-4 shares homology with platelet factor-4 beginning at N-terminal residue 17. CPF-4 consists of MPF-4 disulfide bonded to the 16 N-terminal residues of platelet factor-4. Both MPF-4 and CPF-4 are potent inhibitors of endothelial cell proliferation, approximately 10-100 fold more potent than native or recombinant platelet factor-4, making them useful in the treatment of angiogenic diseases.
    Type: Grant
    Filed: February 14, 1996
    Date of Patent: August 10, 1999
    Assignee: Eli Lilly and Company
    Inventors: Shalley K. Gupta, Jai Pal Singh
  • Methods of increasing nitric oxide synthesis
    Patent number: 5811437
    Abstract: The current invention provides methods for increasing the concentration of nitric oxide (NO) in vascular endothelial cells, comprising administering a compound of formula I ##STR1## Wherein: R is hydrogen, --OH, --O(C.sub.1 -C.sub.4 alkyl), --OCO(C.sub.1 -C.sub.4 alkyl), or --OCOAr where Ar is a phenyl or optionally substituted phenyl;R.sub.1 is R, --C.sub.1, or --F;R.sub.2 is 1-pyrrolidinyl, 1-piperidinyl, or 1-hexamethyleneimino;or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: April 22, 1997
    Date of Patent: September 22, 1998
    Assignee: Eli Lilly and Company
    Inventors: Jai Pal Singh, Danny Lee Wood
  • Pharmaceutical compounds
    Patent number: 5624953
    Abstract: This invention provides novel compounds and pharmaceutical methods comprising the administration of a compound of the Formula I: ##STR1## wherein n, m, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are variables.
    Type: Grant
    Filed: February 2, 1996
    Date of Patent: April 29, 1997
    Assignee: Eli Lilly and Company
    Inventors: Samantha J. Ambler, William F. Heath, Jr., Jai Pal Singh, Colin W. Smith, Lawrence E. Stramm